[HTML][HTML] Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer
M Farshbaf, AY Khosroushahi, S Mojarad-Jabali… - Journal of Controlled …, 2020 - Elsevier
As one of the deadliest diseases, cancer frequently resists existing therapeutics because
they do not target all cells within a progressing tumor, for example both tumor stem and …
they do not target all cells within a progressing tumor, for example both tumor stem and …
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models
Longitudinal models of biomarkers such as tumour size dynamics capture treatment efficacy
and predict treatment outcome (overall survival) of a variety of anticancer therapies …
and predict treatment outcome (overall survival) of a variety of anticancer therapies …
[HTML][HTML] Explainable deep learning for tumor dynamic modeling and overall survival prediction using Neural-ODE
While tumor dynamic modeling has been widely applied to support the development of
oncology drugs, there remains a need to increase predictivity, enable personalized therapy …
oncology drugs, there remains a need to increase predictivity, enable personalized therapy …
Characterizing exposure–response relationship for therapeutic monoclonal antibodies in immuno‐oncology and beyond: challenges, perspectives, and prospects
HI Dai, Y Vugmeyster, N Mangal - Clinical Pharmacology & …, 2020 - Wiley Online Library
Recent data from immuno‐oncology clinical studies have shown the exposure–response (E–
R) relationship for therapeutic monoclonal antibodies (mAbs) was often confounded by …
R) relationship for therapeutic monoclonal antibodies (mAbs) was often confounded by …
[HTML][HTML] A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
Abstract Exposure–response (E–R) analyses are an integral component in the development
of oncology products. Characterizing the relationship between drug exposure metrics and …
of oncology products. Characterizing the relationship between drug exposure metrics and …
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective
Since the 21st Century Cures Act was signed into law in 2016, real‐world data (RWD) and
real‐world evidence (RWE) have attracted great interest from the healthcare ecosystem …
real‐world evidence (RWE) have attracted great interest from the healthcare ecosystem …
[HTML][HTML] Treatment of evolving cancers will require dynamic decision support
Highlights•Cancer is a heterogeneous and evolving disease, yet most drugs are
administered to simply give the maximum dose.•Treatment scheduling currently ignores the …
administered to simply give the maximum dose.•Treatment scheduling currently ignores the …
[HTML][HTML] In silico investigations of multi-drug adaptive therapy protocols
Simple Summary Modern “adaptive therapy” approaches to cancer therapy rely on adjusting
the dose of drugs as the size of the tumor changes. They hold the promise of transforming …
the dose of drugs as the size of the tumor changes. They hold the promise of transforming …
Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
Autologous Chimeric antigen receptor (CAR‐T) cell therapy has been highly successful in
the treatment of aggressive hematological malignancies and is also being evaluated for the …
the treatment of aggressive hematological malignancies and is also being evaluated for the …
Artificial intelligence and mechanistic modeling for clinical decision making in oncology
S Benzekry - Clinical Pharmacology & Therapeutics, 2020 - Wiley Online Library
The amount of “big” data generated in clinical oncology, whether from molecular, imaging,
pharmacological, or biological origin, brings novel challenges. To mine efficiently this source …
pharmacological, or biological origin, brings novel challenges. To mine efficiently this source …